The vast majority of people with extensively drug-resistant
tuberculosis (XDR-TB) diagnosed in the world’s most extensive outbreak have
acquired their infection from another person, not as the result of the failure
of treatment for multidrug-resistant strains of tuberculosis (MDR-TB), N
Sarita Shah told the Conference on Retroviruses and Opportunistic Infections (CROI 2015) in Seattle, USA, on Wednesday.
KwaZulu-Natal province in South Africa has been the setting
for a large outbreak of XDR-TB since 2006, when cases first began to be
identified. XDR-TB is defined as a form of TB that is resistant to isoniazid
and rifampicin, plus any fluoroquinolone and at least one of three injectable
second-line drugs. XDR-TB continues to be a major problem in South Africa
despite the implementation of improved diagnostics, infection control and
treatment regimens.
XDR-TB is very difficult and costly to treat. It is either
acquired through multiple failures of TB treatment regimens, leading to
accumulating resistance to more and more agents, or through transmission from
another person. XDR-TB is not more infectious than drug-sensitive TB.
Although hospitalisation is known to be a risk factor for
acquiring XDR-TB in South Africa, the proportion of XDR-TB that is acquired
through nosocomial transmission (transmission in medical settings) or
transmission in the community is unclear.
Researchers conducted a study of mycobacterial isolates in 400
cases of culture-confirmed XDR-TB in KwaZulu-Natal province, diagnosed between
2011 and 2014. In order to determine whether isolates were linked to others,
they performed genotyping to identify nine mutations conferring resistance to
anti-TB drugs. In cases where a similar genotypic resistance pattern was shared
by more than 20 isolates, the entire genome of each isolate was sequenced to
provide more information about the likely pattern of transmission.
Further strengthening the case for nosocomial transmission,
researchers found that only 21% of isolates came from patients who had received
any treatment for MDR-TB. Seventy-nine per cent of isolates were therefore attributable to
transmission, and in 89% of cases with no previous history of MDR-TB treatment,
the isolate matched at least one other sample.
The researchers found that 47% of all isolates were so
genetically similar, they obviously formed a transmission cluster. The
remainder of isolates belonged to one of 22 clusters of genetically similar
isolates.
A very high
proportion of cases had occurred in people living with HIV (77%), 91% of
whom were receiving antiretroviral treatment. Of these, 66% had an undetectable
viral load at the time of XDR-TB diagnosis.
Sarita Shah of the US Centers for Disease Control and Prevention (CDC) said that
only around half of the cases attributable to transmission had a history of
hospitalisation, suggesting that community settings might be the source of
infection for some patients. More research will be needed to determine whether
community exposure is contributing substantially to the transmission of XDR-TB
in South Africa.
Transmission in healthcare settings could be reduced by
implementation of some basic low-cost interventions such as opening doors and
windows to improve ventilation, separation of people with suspected TB from
other patients, more rapid diagnosis of TB and universal use of drug susceptibility
testing, said Dr Shah, but for many facilities cost remains a barrier to
implementing infection control measures.